Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
Arann Rowe, Louise Mercer, Valentina Casetti, et al.
Journal of Psychopharmacology (2015) Vol. 29, Iss. 2, pp. 197-211
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Albert C. Yang, Shih‐Jen Tsai
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 8, pp. 1689-1689
Open Access | Times Cited: 248
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders
Hans O. Kalkman, Dominik Feuerbach
Cellular and Molecular Life Sciences (2016) Vol. 73, Iss. 13, pp. 2511-2530
Open Access | Times Cited: 153
The effects of ketamine on the mismatch negativity (MMN) in humans – A meta-analysis
Timm Rosburg, Ilonka Kreitschmann‐Andermahr
Clinical Neurophysiology (2015) Vol. 127, Iss. 2, pp. 1387-1394
Closed Access | Times Cited: 119
Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies
Alan S. Lewis, Gerrit I. van Schalkwyk, Michael H. Bloch
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 75, pp. 45-53
Open Access | Times Cited: 73
New drug developments in psychosis: Challenges, opportunities and strategies
Matcheri S. Keshavan, Ashley Lawler, Henry A. Nasrallah, et al.
Progress in Neurobiology (2016) Vol. 152, pp. 3-20
Open Access | Times Cited: 69
Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery
Zhongshan Wu, Hao Cheng, Yi Jiang, et al.
Acta Pharmacologica Sinica (2015) Vol. 36, Iss. 8, pp. 895-907
Open Access | Times Cited: 62
Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor
Fabiana Corsi‐Zuelli, Fernanda Brognara, Gustavo Fernando da Silva Quirino, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 58
Stimulating cognition in schizophrenia: A controlled pilot study of the effects of prefrontal transcranial direct current stimulation upon memory and learning
Natasza Orlov, Derek K. Tracy, Daniel Joyce, et al.
Brain stimulation (2016) Vol. 10, Iss. 3, pp. 560-566
Open Access | Times Cited: 57
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
Marc W. Manseau, Donald Goff
Neurotherapeutics (2015) Vol. 12, Iss. 4, pp. 816-824
Open Access | Times Cited: 50
Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokine Interface in Schizophrenia and Bipolar Disorder
Sebastian Lobentanzer, Geula Hanin, Jochen Klein, et al.
Cell Reports (2019) Vol. 29, Iss. 3, pp. 764-777.e5
Open Access | Times Cited: 49
Drugs, games, and devices for enhancing cognition: implications for work and society
Annette Beatrix Brühl, Barbara J. Sahakian
Annals of the New York Academy of Sciences (2016) Vol. 1369, Iss. 1, pp. 195-217
Open Access | Times Cited: 46
Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms
María Recio-Barbero, Rafael Segarra, Arantzazu Zabala, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 2035-2052
Closed Access | Times Cited: 19
An acetylcholine alpha7 positive allosteric modulator rescues a schizophrenia-associated brain endophenotype in the 15q13.3 microdeletion, encompassing CHRNA7
Natalia Gass, Wolfgang Weber‐Fahr, Alexander Sartorius, et al.
European Neuropsychopharmacology (2016) Vol. 26, Iss. 7, pp. 1150-1160
Open Access | Times Cited: 35
Attention and the Cholinergic System: Relevance to Schizophrenia
Cindy Lustig, Martin Sarter
Current topics in behavioral neurosciences (2015), pp. 327-362
Closed Access | Times Cited: 34
Short- and long-term changes in symptom dimensions among patients with schizophrenia spectrum disorders and different durations of illness: A meta-analysis
Lars de Winter, Jentien M. Vermeulen, Chrisje Couwenbergh, et al.
Journal of Psychiatric Research (2023) Vol. 164, pp. 416-439
Open Access | Times Cited: 10
Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia
Andrea de Bartolomeis, Mariateresa Ciccarelli, Giuseppe De Simone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5945-5945
Open Access | Times Cited: 8
Pharmacotherapy of cognition in schizophrenia
Herbert Y. Meltzer
Current Opinion in Behavioral Sciences (2015) Vol. 4, pp. 115-121
Closed Access | Times Cited: 25
Malingering mental disorders: Clinical assessment
Derek K. Tracy, Keith Rix
BJPsych Advances (2017) Vol. 23, Iss. 1, pp. 27-35
Open Access | Times Cited: 24
α7 Nicotinic Acetylcholine Receptor
Candace M. Jones
Journal of Clinical Psychopharmacology (2018) Vol. 38, Iss. 3, pp. 247-249
Closed Access | Times Cited: 22
In-patient rehabilitation: clinical outcomes and cost implications
Mel Bunyan, Yogesh Ganeshalingam, Ehab Morgan, et al.
BJPsych Bulletin (2016) Vol. 40, Iss. 1, pp. 24-28
Open Access | Times Cited: 21
α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia
Gilda Neves, Anthony A. Grace
Neuropsychopharmacology (2018) Vol. 43, Iss. 8, pp. 1712-1720
Open Access | Times Cited: 21
The response decrease of auditory evoked potentials by repeated stimulation – Is there evidence for an interplay between habituation and sensitization?
Timm Rosburg, Peter Sörös
Clinical Neurophysiology (2015) Vol. 127, Iss. 1, pp. 397-408
Closed Access | Times Cited: 20
Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging
Jason Smucny, Jason R. Tregellas
Journal of Psychopharmacology (2017) Vol. 31, Iss. 7, pp. 801-811
Open Access | Times Cited: 19
A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia
Yong‐Ku Kim, Joonho Choi, Seon‐Cheol Park
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 4, pp. 734-734
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top